Comparative Efficacy of Donepezil and Lamotrigine in Modulating NFκB, PPARγ, and NLRP3 Inflammasome Pathways in Experimental Colitis
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.70141 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Nourhan S Abdeltwab Desoky und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, Giz…. Hauptthemen laut MEDLINE: Donepezil, Lamotrigine, Colitis, Ulcerative. Die Arbeit nennt 45 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Ulcerative colitis (UC) is a persistent inflammatory bowel disorder characterized by systemic inflammation and oxidative stress. This study compared the therapeutic potential of lamotrigine and donepezil in an acetic acid (AA)‐induced UC rat model. Fifty‐six male Wistar rats were divided into seven groups: control, AA (4% v/v), donepezil (5 mg/kg), lamotrigine (10 mg/kg), prednisolone + AA, donepezil + AA, and lamotrigine + AA. Treatments were trans‐rectally administered for 12 days before and 2 days after UC induction. Macroscopic and histological damage, oxidative stress markers (myeloperoxidase, malondialdehyde, and nitric oxide), antioxidant levels (glutathione), cytokines, and apoptotic markers were assessed. Donepezil and lamotrigine reduced AA‐induced damage, decreased oxidative stress, and restored the glutathione level. Both drugs lowered proinflammatory cytokines (e.g., interleukin‐1β and tumor necrosis factor‐α) and increased interleukin‐10. Mechanistically, they activated peroxisome proliferator‐activated receptor‐gamma (PPARγ), inhibited nuclear factor kappa B (NFκB), and modulated apoptosis (BAX/Bcl‐2 ratio, caspase‐1). Donepezil and lamotrigine show promise in UC therapy by targeting oxidative stress, inflammation, and apoptosis, supporting their potential repurposing for inflammatory bowel disease treatment. Further research is needed for clinical validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, Giza, Egypt.
- Department of Anatomy and Embryology, Faculty of Medicine, Cairo University, Cairo, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
ORCID-Profile: Nourhan S Abdeltwab Desoky, Heba M Mahmoud
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Abdeltwab Desoky, N. S., Ahmed, M. A. E., Aboulhoda, B. E., Abo-Youssef, A. M., & Mahmoud, H. M. (2025). Comparative Efficacy of Donepezil and Lamotrigine in Modulating NFκB, PPARγ, and NLRP3 Inflammasome Pathways in Experimental Colitis. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70141
Vancouver
Abdeltwab Desoky NS, Ahmed MAE, Aboulhoda BE, Abo-Youssef AM, Mahmoud HM. Comparative Efficacy of Donepezil and Lamotrigine in Modulating NFκB, PPARγ, and NLRP3 Inflammasome Pathways in Experimental Colitis. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70141
BibTeX
@article{AbdeltwabDesoky2025,
author = {Abdeltwab Desoky, Nourhan S and Ahmed, Maha A E and Aboulhoda, Basma Emad and Abo-Youssef, Amira M and Mahmoud, Heba M},
title = {Comparative Efficacy of Donepezil and Lamotrigine in Modulating NFκB, PPARγ, and NLRP3 Inflammasome Pathways in Experimental Colitis},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.70141}
}
EUVIMED